153 related articles for article (PubMed ID: 38669897)
1. Leishmania vaccine development: A comprehensive review.
Saini I; Joshi J; Kaur S
Cell Immunol; 2024; 399-400():104826. PubMed ID: 38669897
[TBL] [Abstract][Full Text] [Related]
2. Vaccines for leishmaniasis: from proteome to vaccine candidates.
Schroeder J; Aebischer T
Hum Vaccin; 2011; 7 Suppl():10-5. PubMed ID: 21245661
[TBL] [Abstract][Full Text] [Related]
3. Identifying vaccine targets for anti-leishmanial vaccine development.
Sundar S; Singh B
Expert Rev Vaccines; 2014 Apr; 13(4):489-505. PubMed ID: 24606556
[TBL] [Abstract][Full Text] [Related]
4. Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis.
Duthie MS; Reed SG
Clin Vaccine Immunol; 2017 Jul; 24(7):. PubMed ID: 28515135
[TBL] [Abstract][Full Text] [Related]
5. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.
Ahmed SB; Touihri L; Chtourou Y; Dellagi K; Bahloul C
Vaccine; 2009 Jan; 27(1):99-106. PubMed ID: 18951941
[TBL] [Abstract][Full Text] [Related]
6. Vaccine candidates against leishmania under current research.
Iborra S; Solana JC; Requena JM; Soto M
Expert Rev Vaccines; 2018 Apr; 17(4):323-334. PubMed ID: 29589966
[TBL] [Abstract][Full Text] [Related]
7. Status of vaccine research and development of vaccines for leishmaniasis.
Gillespie PM; Beaumier CM; Strych U; Hayward T; Hotez PJ; Bottazzi ME
Vaccine; 2016 Jun; 34(26):2992-2995. PubMed ID: 26973063
[TBL] [Abstract][Full Text] [Related]
8. Chitosan Nanoparticles Loaded with Whole and Soluble Leishmania Antigens, and Evaluation of Their Immunogenecity in a Mouse Model of Leishmaniasis.
Hojatizade M; Soleymani M; Tafaghodi M; Badiee A; Chavoshian O; Jaafari MR
Iran J Immunol; 2018 Dec; 15(4):281-293. PubMed ID: 30593742
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of vaccinal effectiveness of preparations containing membrane antigens of Leishmania (L.) amazonensis in experimental cutaneous leishmaniasis model.
Ribeiro JG; Ferreira AS; Macedo SRA; Rossi NRDLP; da Silva MCP; Guerra RNM; de Barros NB; Nicolete R
Int Immunopharmacol; 2017 Jun; 47():227-230. PubMed ID: 28433944
[TBL] [Abstract][Full Text] [Related]
10. Successful vaccination against Leishmania chagasi infection in BALB/c mice with freeze-thawed Leishmania antigen and Corynebacterium parvum.
Vilela Mde C; Gomes DC; Marques-da-Silva Ede A; Serafim TD; Afonso LC; Rezende SA
Acta Trop; 2007; 104(2-3):133-9. PubMed ID: 17919443
[TBL] [Abstract][Full Text] [Related]
11. Translating Observations From Leishmanization Into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies Against
Seyed N; Peters NC; Rafati S
Front Immunol; 2018; 9():1227. PubMed ID: 29922288
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
[TBL] [Abstract][Full Text] [Related]
13. Leishmaniasis in humans: drug or vaccine therapy?
Ghorbani M; Farhoudi R
Drug Des Devel Ther; 2018; 12():25-40. PubMed ID: 29317800
[TBL] [Abstract][Full Text] [Related]
14. Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen.
Zahedifard F; Gholami E; Taheri T; Taslimi Y; Doustdari F; Seyed N; Torkashvand F; Meneses C; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
PLoS Negl Trop Dis; 2014 Mar; 8(3):e2751. PubMed ID: 24675711
[TBL] [Abstract][Full Text] [Related]
15. Cross-protective efficacy from a immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis.
Martins VT; Lage DP; Duarte MC; Costa LE; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Tavares CA; Coelho EA
Parasite Immunol; 2016 Feb; 38(2):108-17. PubMed ID: 26756314
[TBL] [Abstract][Full Text] [Related]
16. Vaccinomics strategy to concoct a promising subunit vaccine for visceral leishmaniasis targeting sandfly and leishmania antigens.
Ojha R; Pandey RK; Prajapati VK
Int J Biol Macromol; 2020 Aug; 156():548-557. PubMed ID: 32311400
[TBL] [Abstract][Full Text] [Related]
17. Case study for a vaccine against leishmaniasis.
Alvar J; Croft SL; Kaye P; Khamesipour A; Sundar S; Reed SG
Vaccine; 2013 Apr; 31 Suppl 2():B244-9. PubMed ID: 23598489
[TBL] [Abstract][Full Text] [Related]
18. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
Nagill R; Kaur S
Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with whole-cell killed or recombinant leishmanial protein and toll-like receptor agonists against Leishmania tropica in BALB/c mice.
Rostamian M; Bahrami F; Niknam HM
PLoS One; 2018; 13(9):e0204491. PubMed ID: 30248142
[TBL] [Abstract][Full Text] [Related]
20. Peptide Vaccines for Leishmaniasis.
De Brito RCF; Cardoso JMO; Reis LES; Vieira JF; Mathias FAS; Roatt BM; Aguiar-Soares RDDO; Ruiz JC; Resende DM; Reis AB
Front Immunol; 2018; 9():1043. PubMed ID: 29868006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]